Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Medical Oncology
•
Neurology
Do you utilize tumor treating fields in patients with anaplastic Pleomorphic Xanthoastrocytoma PXA III?
Related Questions
Are you offering Lutathera for multiple recurrent meningiomas?
What experience do you have with paralysis or myasthenia like symptoms developing on Temozolomide?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
Is there a role for bevacizimab (IV or IA) for steroid refractory radionecrosis for AVM?
When is the best time to try targeted therapy in adult-type diffuse non-IDH glioma?
What approach do you use when treating adult diffuse gliomas with H3-G34 mutations, now classified into their own category under the 2021 glioma guidelines?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
